Pharmacokinetic considerations of regional administration and drug targeting: Influence of site of input in target tissue and flux of binding protein

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 4, 1996, Pages 369-387

  Rowland, Malcolm ^a   McLachlan, Andrew ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Drug delivery; Drug targeting index; Flux of bound drug; Permeability; Selective advantage

Indexed keywords

ARTICLE; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TRANSPORT; PHARMACOKINETICS; PRIORITY JOURNAL; THEORETICAL STUDY;

DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PROTEIN BINDING;

EID: 0030485637     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353518     Document Type: Article

References (30)

1. C. A. Hunt, R. D. MacGregor, and R. A. Siegel. Engineering targeted in vivo drug delivery. I. The physiological and physiochemical principles governing opportunities and limitations. Pharm. Res. 3:333-344 (1986).
2. S. Øie and J-D. Huang. Influence of administration route on drug delivery to a target organ. J. Pharm. Sci. 70:1344-1347 (1981).
3. R. L. Dedrick. Interspecies scaling of regional delivery. J. Pharm. Sci. 75:1047-1052 (1986).
4. U. G. Eriksson and T. N. Tozer. Pharmacokinetic evaluation of regional drug delivery. Acta Pharm. Jugoslavia 37:331-344 (1987).
5. R. A. Siegel, R. D. MacGregor, and C. A. Hunt. Comparison and critique of two models of regional drug delivery. J. Pharmacokin. Biopharm. 19:365-372 (1991).
6. H. Suzuki, D. Nakai, T. Seita, and Y. Sugiyama. Design of a drug delivery system for targeting based on pharmacokinetic considerations. Adv. Drug Delivery Rev. 19:335-357, 1996.
7. V. J. Stella and A. S. Kearney. Pharmacokinetics of drug targeting: specific implications for targeting via prodrugs in drug targeting and delivery. In Handbook of Pharmacology, Vol. 100, Academic Press, San Diego, 1991, pp. 71-103.
8. M. Weiss. On pharmacokinetics in target tissues. Biopharm. Drug Dispos. 6:57-66 (1985).
9. A. Aubree-Lecat, M-C. Duban, S. Demignot, M. Domurado, P. Fiurnie, and D. Domurado. Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target. J. Pharmacokin. Biopharm. 21:75-98 (1993).
10. T. Sakane, M. Nakatsu, A. Yamamoto, M. Hashida, H. Sezaki, S. Yamashita, and T. Nadai. Assessment of drug disposition in the perfused rat brain by statistical moment analysis. Pharm. Res. 8:683-689 (1991).
11. K. Ohkouchi, H. Imoto, Y. Takakura, M. Hashida, and H. Sezaki. Disposition of anti-cancer drugs after bolus administration into a tissue-isolated tumour perfusion system. Cancer Res. 50:1640-1644 (1990).
12. R. Atsumi, K. Endo, T. Kakutani, Y. Takakura, M. Hashida, and H. Sezaki. Disposition characteristics of mitomycin C-dextran conjugate in normal and tumour-bearing muscles of rabbits. Cancer Res. 47:5546-5551 (1987).
13. K. Mihara, M. Mori, T. Hojo, Y. Takakura, H. Sezaki, and M. Hashida. Disposition characteristics of model macromolecules in the perfused rat kidney. Biol. Pharm. Bull. 16:158-162 (1993).
14. H. Nara, M. Masegi, T. Hatono, and M. Hashida. Pharmacokinetic analysis of drug absorption from muscle based on a physiological diffusion model: effect of molecular size on absorption. Pharm. Res. 9:161-168 (1992).
15. B. P. Sipos and H. Brem. New delivery systems for brain tumour therapy. Neurol. Clin. 13:813-825 (1995).
16. M. F. Flessner and R. L. Dedrick. Monoclonal antibody delivery to intraperitoneal tumours in rats: effects of route of administration and intraperitoneal solution osmolality. Cancer Res. 54:4376-4384 (1994).
17. S. G. Owen, H. W. Francis, and M. S. Robert. Disappearance kinetics of solutes from synovial fluid after intra-articular injection. Br. J. Clin. Pharmacol. 38:349-355 (1994).
18. V. J. Stella and K. J. Himmelstein. Prodrugs and site-specific drugs delivery. J. Med. Chem. 23:1277-1282 (1980).
19. F. A. Omar, H. Farag, and N. Bodor. Synthesis and evaluation of a redox chemical delivery system for brain-enhanced dopamine containing an activated carbonate-type ester. J. Drug Target. 2:309-316 (1994).
20. N. Bodor. Designing safer ophthalmic drugs by soft drug approaches. J. Ocular Pharmacol. 10:3-15 (1994).
21. M. E. Brewster, K. Raghavan, E. Pop, and N. Bodor. Enhanced delivery of ganciclovir to the brain through the use of redox targeting. Antimicrob. Agents Chemother. 38:817-823 (1994).
22. S. W. Martin, A. J. Stevens, B. S. Brennan, M. L. Reis, L. A. Gifford, M. Rowland, and J. B. Houston. Regional drug delivery: Permeability characteristics of the rat 6-day-old air pouch model of inflammation. Pharm. Res. 12:1980-1986 (1995).
23. L. W. Seymour. Passive tumour targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9:135-187 (1992).
24. C. Sung, R. J. Youle, and R. L. Dedrick. Pharmacokinetic analysis of immunotoxin uptake in solid tumours: role of plasma kinetics, capillary permeability and binding. Cancer Res. 50:7382-7292 (1990).
25. Y. F. Huang, R. N. Upton, W. B. Runciman, and L. E. Mather. Insight into interstitial drug disposition: Lymph concentrations of lidocaine, procainamide and meperidine in the hindquarters of unanaesthetized and anaesthetized sheep. J. Pharmacol. Exp. Ther. 256:69-75 (1991).
26. M. Nishikawa, A. Kamijo, T. Fujita, Y. Takakura, H. Sezaki, and M. Hashida. Synthesis and pharmacokinetics of new liver-specific carrier, glycosylated carboxymethyldextran and its application to drug targeting. Pharm. Res. 10:1253-1261 (1993).
27. E. J. F. Franseen, F. Moolenaar, D. Dezeeuw, and D. K. F. Meijer. Drug targeting to the kidney with low molecular weight proteins. Adv. Drug Delivery Rev. 14:67-88 (1994).
28. L. J. Nugent and R. K. Jain. Two-compartment model for plasma pharmacokinetics of individual vessels. J. Pharmacokin. Biopharm. 12:451-462 (1984).
29. C-H. Chou, A. J. McLachlan, and M. Rowland. Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. J. Pharmacol. Exp. Ther. 275:933-940 (1995).
30. A. V. Boddy, L. J. Aarons, and K. Petrak. Steady state considerations using a three-compartment model. Pharm. Res. 6:367-372 (1989).